Cells Fuse Their Nuclear Envelope to Build Molecular Gateways, Study Finds

Every cell in the human body faces a fundamental architectural challenge: its genetic material is locked away inside the nucleus, wrapped in a double-layered protective envelope, yet thousands of molecules must cross that barrier every minute for the cell to stay alive. The gateways that make this possible are nuclear pore complexes, elaborate protein channels that pierce both membranes of the nuclear envelope and act as highly selective checkpoints, waving in proteins and sending messenger RNA out to the cytoplasm. But before such a pore can be assembled, the cell must perform a delicate feat of engineering: it has to punch an opening through two stacked lipid membranes and then seal the exposed edges seamlessly, without ever breaching the barrier that separates the genome from the rest of the cell. How this fusion is accomplished has been one of the enduring puzzles of cell biology, and now researchers at ETH Zurich, working with partners in Switzerland and Germany, report that they have solved it.

The new studies, published in the journal Molecular Cell, come from the Institute of Biochemistry at ETH Zurich, led by professors Ulrike Kutay, Karsten Weis and Madhav Jagannathan, together with colleagues from the University of Fribourg, the Paul Scherrer Institute, the European Molecular Biology Laboratory and RWTH Aachen University. Their work demonstrates for the first time that two molecular tools are required for the two membranes of the nuclear envelope to fuse correctly: an enzyme called Torsin-1A and a complex built from multiple copies of a protein known as CLCC1 in human cells. In fungi, the same job is carried out by the related proteins Brl1 and Brr6, a detail that underscores how deeply conserved this fusion machinery is across the tree of life, from yeast to flies to mammals.

Until now, scientists knew that a defect in Torsin-1A brings nuclear pore assembly to a halt, with fatal consequences for the cell, but the mechanics of the partnership remained obscure. The ETH-led teams have now shown how the cooperation works at a molecular level. Torsin-1A binds to CLCC1 and helps several of these building blocks join together into a larger assembly. Once the complex is formed, Torsin-1A escorts it to the site of pore assembly on the nuclear envelope, positioning it exactly where the two membranes must merge. In other words, the enzyme acts both as a chaperone that assembles the fusion machinery and as a guide that delivers it to its workplace.

The fusion mechanism itself caught the researchers off guard. Using computer simulations, the teams hypothesised that CLCC1 proteins, or their fungal relatives Brl1 and Brr6, forge a temporary channel inside the nuclear envelope. This channel allows lipid molecules to flow across the bilayers, a movement that is normally restricted. The resulting lipid exchange destabilises the local membrane structure and forces the inner and outer nuclear membranes to fuse with one another. Daria Maslennikova, the first author of one of the studies, who completed her doctorate in Kutay’s group, said the teams had not expected such a mechanism. The idea that a protein complex could catalyse membrane merger by opening a lipid conduit, rather than by directly pulling the membranes together, adds a striking new entry to the catalogue of ways cells remodel their internal boundaries.

The stakes of this microscopic operation become clear when it fails. In higher organisms such as mammals, flies and fungi, the genome is enclosed in a nucleus bounded by a nuclear envelope of two stacked membranes. Nuclear pores are the only conduits through the envelope, and each one must be assembled by fusing the inner and outer membranes at a single point. If fusion stalls, pore assembly stalls with it, and the vital traffic of proteins and RNA between nucleus and cytoplasm is compromised. Cells that cannot build their pores cannot survive, which is why the machinery described in the new papers is so critical, and why mutations that impair it produce disease.

That disease is primary dystonia, specifically DYT1 dystonia, a rare and currently incurable neurological movement disorder that affects roughly six in every 100,000 people worldwide. The condition usually begins in childhood and manifests as painful muscle spasms and abnormal postures that can be severely disabling. Treatment options today are limited to alleviating symptoms, chiefly through physiotherapy or injections of botulinum toxin, and no therapy addresses the underlying cause. The new findings give that cause a molecular identity: in people with primary dystonia, a mutation in the Torsin1A gene prevents the Torsin1A molecule from functioning correctly, leaving the CLCC1 complex without sufficient support to carry out its membrane-fusion duties during nuclear pore assembly.

Crucially, the research also points toward a possible intervention. In experiments with fruit flies, the researchers showed that artificially increasing CLCC1 levels can correct defects that arise, for example, during germline cell development, even when Torsin-1A function is impaired. This suggests that the CLCC1 complex is the limiting factor in the fusion reaction, and that boosting its availability can compensate for a weakened partner enzyme. The result transforms a fundamental cell-biological discovery into a concrete therapeutic hypothesis: if the balance between Torsin1A and CLCC1 can be shifted in patients, the cellular defects that drive dystonia might be partially or fully corrected.

One lingering mystery is why the same Torsin1A mutation produces symptoms in only about a third of the people who carry it. The researchers speculate that person-specific differences in CLCC1 protein levels may contribute to this variable penetrance, meaning that individuals with naturally higher amounts of the fusion protein might be better buffered against the effects of the faulty enzyme. If that hypothesis holds up, measuring or modulating CLCC1 levels could become not only a treatment strategy but also a way to predict who is at risk. Ulrike Kutay noted that the finding helps the team envision a possible therapy, with one potential strategy being to boost CLCC1 production or to prevent the protein from being broken down inside cells. This approach has already shown success in human cell cultures and in fruit flies, although whether it can be translated to patients must first be evaluated in further clinical studies and drug screens.

Beyond the immediate therapeutic horizon, the work opens several new lines of inquiry. The teams plan to investigate additional relatives of Torsin1A; human cells contain other torsins whose precise functions remain unknown, and the tools and concepts developed in this study should now make those functions accessible to experiment. In collaboration with plant scientists, Kutay, Weis, Jagannathan and their colleagues also aim to determine whether similar molecules and fusion mechanisms operate in plants, which would indicate that the pathway is a universal feature of eukaryotic life. For the researchers, the journey from a basic question about how cells punch holes in their own nucleus to a candidate therapy for a devastating childhood disease is a powerful illustration of why curiosity-driven research matters. Fundamental discoveries about the smallest building blocks of life, they argue, remain the most reliable starting point for the medicines of tomorrow.

Subject of Research: Membrane fusion mechanism of nuclear pore complex assembly and its link to DYT1 dystonia

Article Title: How cells make their command center accessible

Article References: How cells make their command center accessible. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: nuclear pore complex, nuclear envelope, membrane fusion, Torsin-1A, CLCC1, DYT1 dystonia, ETH Zurich, Molecular Cell, cell biology, neurological disorder, gene mutation, basic research